Drug Trial Radar · NCT01508026
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
Last checked: Nov 20, 2026Latest source record: Apr 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,161
Actual
Start
Jan 2012
Primary completion
Mar 2013
Study completion May 2013
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jan 11, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension.
Conditions
- Stage 1 Hypertension
- Stage 2 Hypertension
Interventions
Nebivolol and Valsartan 1Drug
Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration
Nebivolol and Valsartan 2Drug
Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration
Nebivolol and Valsartan 3Drug
Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration
Nebivolol 1Drug
Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration
Nebivolol 2Drug
Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration
Valsartan 1Drug
Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration
Valsartan 2Drug
Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration
PlaceboDrug
Dose matched placebo, oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Sitting Diastolic Blood Pressure (DBP)Time frame: from basline to Week 8
Locations
413 sites in 1 country. Site status is shown where the registry gives one.
Forest Investigative Site 1750
Birmingham, Alabama
Forest Investigative Site 1038
Birmingham, Alabama
Forest Investigative Site 1308
Birmingham, Alabama
Forest Investigative Site 1192
Birmingham, Alabama
Forest Investigative Site 1005
Birmingham, Alabama
Forest Investigative Site 1047
Foley, Alabama
Forest Investigative Site 1717
Gulf Shores, Alabama
Forest Investigative Site 1056
Mobile, Alabama
Forest Investigative Site 1719
Muscle Shoals, Alabama
Forest Investigative Site 1145
Glendale, Arizona
Forest Investigative Site 1703
Goodyear, Arizona
Forest Investigative Site 1757
Mesa, Arizona
Forest Investigative Site 1170
Phoenix, Arizona
Forest Investigative Site 1238
Phoenix, Arizona
Forest Investigative Site 1204
Phoenix, Arizona
Forest Investigative Site 1755
Phoenix, Arizona
Forest Investigative Site 1259
Phoenix, Arizona
Forest Investigative Site 1001
Phoenix, Arizona
Forest Investigative Site 1078
Scottsdale, Arizona
Forest Investigative Site 1225
Tempe, Arizona
Forest Investigative Site 1712
Tempe, Arizona
Forest Investigative Site 1089
Tempe, Arizona
Forest Investigative Site 1065
Tucson, Arizona
Forest Investigative Site 1340
Tucson, Arizona
Forest Investigative Site 1331
Tucson, Arizona
Forest Investigative Site 1290
Little Rock, Arkansas
Forest Investigative Site 1138
Little Rock, Arkansas
Forest Investigative Site 1371
Pine Bluff, Arkansas
Forest Investigative Site 1220
Searcy, Arkansas
Forest Investigative Site 1063
Buena Park, California
Forest Investigative Site 1743
Burbank, California
Forest Investigative Site 1006
Carmichael, California
Forest Investigative Site 1384
Chino, California
Forest Investigative Site 1190
Chula Vista, California
Forest Investigative Site 1178
Costa Mesa, California
Forest Investigative Site 1043
Diamond Bar, California
Forest Investigative Site 1362
Encinitas, California
Forest Investigative Site 1144
Fresno, California
Forest Investigative Site 1095
Fresno, California
Forest Investigative Site 1710
Garden Grove, California
Showing 40 of 413 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.